PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research report report published on Thursday,Benzinga reports. They currently have a $21.00 price target on the stock.

Separately, B. Riley reduced their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, November 25th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.67.

PDS Biotechnology Trading Down 2.4 %

NASDAQ:PDSB opened at $1.23 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. The firm has a 50-day moving average of $1.44 and a 200-day moving average of $2.27. The company has a market cap of $46.98 million, a PE ratio of -1.06 and a beta of 1.68. PDS Biotechnology has a one year low of $1.13 and a one year high of $5.00.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP boosted its stake in PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after acquiring an additional 10,837 shares during the last quarter. Raymond James Financial Inc. purchased a new position in PDS Biotechnology in the fourth quarter valued at about $26,000. Jane Street Group LLC purchased a new position in PDS Biotechnology in the fourth quarter valued at about $58,000. Blair William & Co. IL boosted its stake in PDS Biotechnology by 29.4% in the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock valued at $257,000 after acquiring an additional 35,757 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in PDS Biotechnology by 9.8% in the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after acquiring an additional 37,142 shares during the last quarter. 26.84% of the stock is owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.